Your browser doesn't support javascript.
loading
Increased toxicities in children with Burkitt lymphoma treated with rituximab: Experience from a tertiary cancer center in India.
Srinivasan, Shyam; Roy Moulik, Nirmalya; Kc, Anand; Narula, Gaurav; Sankaran, Hari; Prasad, Maya; Dhamne, Chetan; Cheriyalinkal Parambil, Badira; Shah, Sneha; Shet, Tanuja; Sridhar, Epari; Gujral, Sumeet; Banavali, Shripad.
Afiliação
  • Srinivasan S; Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Roy Moulik N; Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Kc A; Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Narula G; Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Sankaran H; Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Prasad M; Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Dhamne C; Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Cheriyalinkal Parambil B; Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Shah S; Department of Nuclear Medicine, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Shet T; Department of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Sridhar E; Department of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Gujral S; Department of Pathology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
  • Banavali S; Department of Pediatric Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Pediatr Blood Cancer ; 67(11): e28682, 2020 11.
Article em En | MEDLINE | ID: mdl-32865865
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Burkitt / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Rituximab / Antineoplásicos Imunológicos Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Pediatr Blood Cancer Assunto da revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Índia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma de Burkitt / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Rituximab / Antineoplásicos Imunológicos Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Pediatr Blood Cancer Assunto da revista: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Índia